T3D Therapeutics, based in Research Triangle Park, NC, is a clinical-stage drug development company focused on treatments for Alzheimer’s disease. It is developing T3D-959, an orally administered, brain-penetrating small molecule dual nuclear receptor agonist designed to improve glucose and lipid metabolism dysfunctions present in AD and other neurodegenerative disorders. The company is led by CEO John Didsbury, Ph.D., and CMO Warren Strittmatter, M.D. T3D closed a $15M financing, with a cornerstone investor and support from the National Institute on Aging. The company intends to use the proceeds to begin the Phase 2 PIONEER study of T3D-959, a double-blind, placebo-controlled, parallel-group safety and efficacy trial. PIONEER is expected to initiate patient dosing in early 2020 and to enroll up to 256 adults with mild-to-moderate Alzheimer’s disease (MMSE 16–26) who will receive one of three doses or placebo for 24 weeks.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2019